PMID- 23000427
OWN - NLM
STAT- MEDLINE
DCOM- 20130403
LR  - 20211021
IS  - 1096-0945 (Electronic)
IS  - 0014-4800 (Linking)
VI  - 94
IP  - 1
DP  - 2013 Feb
TI  - Dual role of Response gene to complement-32 in multiple sclerosis.
PG  - 17-28
LID - S0014-4800(12)00127-X [pii]
LID - 10.1016/j.yexmp.2012.09.005 [doi]
AB  - Response gene to complement (RGC)-32 is a novel molecule that plays an important 
      role in cell proliferation. We investigated the expression of RGC-32 in multiple 
      sclerosis (MS) brain and in peripheral blood mononuclear cells (PBMCs) obtained 
      from patients with relapsing-remitting multiple sclerosis. We found that CD3(+), 
      CD68(+), and glial fibrillar acidic protein (GFAP)(+) cells in MS plaques 
      co-localized with RGC-32. Our results show a statistically significant decrease 
      in RGC-32 mRNA expression in PBMCs during relapses when compared to the levels in 
      stable MS patients. This decrease might be useful in predicting disease activity 
      in patients with relapsing-remitting MS. RGC-32 expression was also correlated 
      with that of FasL mRNA during relapses. FasL mRNA expression was significantly 
      reduced after RGC-32 silencing, indicating a role for RGC-32 in the regulation of 
      FasL expression. In addition, the expression of Akt1, cyclin D1, and IL-21 mRNA 
      was significantly increased during MS relapses when compared to levels in healthy 
      controls. Furthermore, we investigated the role of RGC-32 in TGF-beta-induced 
      extracellular matrix expression in astrocytes. Blockage of RGC-32 using small 
      interfering RNA significantly inhibits TGF-beta induction of procollagen I, 
      fibronectin and of the reactive astrocyte marker alpha-smooth muscle actin (alpha-SMA). 
      Our data suggest that RGC-32 plays a dual role in MS, both as a regulator of 
      T-cells mediated apoptosis and as a promoter of TGF-beta-mediated profibrotic 
      effects in astrocytes.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Tegla, Cosmin A
AU  - Tegla CA
AD  - Department of Neurology, University of Maryland School of Medicine, Baltimore, MD 
      21201, USA.
FAU - Cudrici, Cornelia D
AU  - Cudrici CD
FAU - Azimzadeh, Philippe
AU  - Azimzadeh P
FAU - Singh, Anil K
AU  - Singh AK
FAU - Trippe, Richard 3rd
AU  - Trippe R 3rd
FAU - Khan, Ali
AU  - Khan A
FAU - Chen, Hegang
AU  - Chen H
FAU - Andrian-Albescu, Maria
AU  - Andrian-Albescu M
FAU - Royal, Walter 3rd
AU  - Royal W 3rd
FAU - Bever, Christopher
AU  - Bever C
FAU - Rus, Violeta
AU  - Rus V
FAU - Rus, Horea
AU  - Rus H
LA  - eng
GR  - I01 BX001458/BX/BLRD VA/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20120919
PL  - Netherlands
TA  - Exp Mol Pathol
JT  - Experimental and molecular pathology
JID - 0370711
RN  - 0 (ACTA2 protein, human)
RN  - 0 (Actins)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (CD3 Complex)
RN  - 0 (CD68 antigen, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Collagen Type I)
RN  - 0 (FASLG protein, human)
RN  - 0 (Fas Ligand Protein)
RN  - 0 (Fibronectins)
RN  - 0 (Glial Fibrillary Acidic Protein)
RN  - 0 (Interleukins)
RN  - 0 (Muscle Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (RGCC protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Transforming Growth Factor beta)
RN  - 136601-57-5 (Cyclin D1)
RN  - 9007-36-7 (Complement System Proteins)
RN  - EC 2.7.11.1 (Akt1 protein, mouse)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - MKM3CA6LT1 (interleukin-21)
SB  - IM
MH  - Actins/metabolism
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antigens, CD/analysis
MH  - Antigens, Differentiation, Myelomonocytic/analysis
MH  - Apoptosis
MH  - Astrocytes/metabolism
MH  - Brain/*metabolism
MH  - CD3 Complex/analysis
MH  - Cell Cycle Proteins/genetics/*metabolism
MH  - Cell Proliferation
MH  - Collagen Type I/metabolism
MH  - Complement System Proteins/metabolism
MH  - Cyclin D1/biosynthesis/genetics
MH  - Extracellular Matrix/metabolism
MH  - Fas Ligand Protein/genetics
MH  - Female
MH  - Fibronectins/metabolism
MH  - Glial Fibrillary Acidic Protein
MH  - Humans
MH  - Interleukins/biosynthesis/genetics
MH  - Leukocytes, Mononuclear/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/*metabolism
MH  - Muscle Proteins/genetics/*metabolism
MH  - Nerve Tissue Proteins/genetics/*metabolism
MH  - Proto-Oncogene Proteins c-akt/biosynthesis/genetics
MH  - RNA Interference
MH  - RNA, Messenger/genetics/metabolism
MH  - RNA, Small Interfering
MH  - T-Lymphocytes/metabolism
MH  - Transforming Growth Factor beta/metabolism
MH  - Young Adult
EDAT- 2012/09/25 06:00
MHDA- 2013/04/04 06:00
CRDT- 2012/09/25 06:00
PHST- 2012/07/25 00:00 [received]
PHST- 2012/09/10 00:00 [accepted]
PHST- 2012/09/25 06:00 [entrez]
PHST- 2012/09/25 06:00 [pubmed]
PHST- 2013/04/04 06:00 [medline]
AID - S0014-4800(12)00127-X [pii]
AID - 10.1016/j.yexmp.2012.09.005 [doi]
PST - ppublish
SO  - Exp Mol Pathol. 2013 Feb;94(1):17-28. doi: 10.1016/j.yexmp.2012.09.005. Epub 2012 
      Sep 19.